Drug Profile
Research programme: anti-fungal monoclonal antibodies
Alternative Names: MVX 505; PCP-Antibody - MiniVaxLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Rochester
- Developer MiniVax; University of Rochester
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pneumocystis pneumonia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumocystis pneumonia in USA (IV, Infusion)